COMP <GO>
EBS vs SPRY // REVENUE GROWTH (YOY)
Emergent BioSolutions Inc. (NYSE) VS. ARS Pharmaceuticals Inc. (NASDAQ) • 15-METRIC TALLY: EBS 7
— SPRY 1
▲ REVENUE GROWTH (YOY) LEADER: SPRY
LAST: $7.22 (+1.83%) • MKT CAP: $370.2M
revenue-growth
-28.80%
LAST: $3.66 (+0.27%) • MKT CAP: $364.0M
revenue-growth
-5.50%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (EBS VS. SPRY)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | EBS | SPRY | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 56.10% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 8.90% | -35.00% | +43.90 | EBS | /roic <GO> |
| EV/EBITDA & P/E Valuation | 6.6x | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | 13.50% | -60.00% | +73.50 | EBS | /operating-margins <GO> |
| Net Profit Margin | 7.10% | -60.00% | +67.10 | EBS | /net-margins <GO> |
| Revenue Growth (YoY) ACTIVE | -28.80% | -5.50% | -23.30 | SPRY | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 1.41 | 0.20 | +1.21 | EBS | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 2/9 | +6.00 | EBS | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 53.0 | 29.8 | +23.20 | EBS | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 6.5x | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $370.2M | $364.0M | $6.2M | EBS | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | EBS REV | SPRY REV | EBS GROSS % | SPRY GROSS % | EBS FCF | SPRY FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $742.9M | $84.3M | 56.1% | — | $156.8M | -$171.2M |
| FY 2024 | $1.04B | $89.1M | 34.7% | — | $35.8M | $13.0M |
| FY 2023 | $1.05B | $30.0K | — | — | -$206.3M | -$59.3M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
EBS // BETA —
SPRY // BETA —